The practice of patenting genes, which had largely faded from the headlines, has suddenly attracted a swarm of critics. The blitz includes an op-ed article in The New York Times by best-selling-novelist-turned-patent-gadfly Michael Crichton, a torrent of posts and comments on patent law blogs, and a disturbingly sweeping piece of intellectual property legislation.

The first salvo, introduced in the House of Representatives in early February, was bill H.R. 977, the “Genomic Research and Accessibility Act.” The bill would insert a change in the U.S. patent code which reads, in its entirety: “Notwithstanding any other provision of law, no patent may be obtained for a nucleotide sequence, or its functions or correlations, or the naturally occurring products it specifies.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]